An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
VERDICT
The label
Markup
read at $154.44
Novartis AG holds its Markup at $154.44.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-05
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 3 days
Price
$154.44
Valuation
23.33 trailing · 15.64 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.49
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 17% discount to our $180.00 fair value, 0.80% revenue growth.
Read at
$154.44
23.33 P/E · 15.64 fwd
Our fair value
$180.00
17% discount
Analyst target (avg)
$153.58
-1% to current
Target low $123.00Analyst target rangeTarget high $180.00
▲ current $154.44 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$154.44
you are here
Conservative
$162.90
+5%
Analyst avg
$153.58
-1%
Our fair value
$180.00
+17%
Analyst high
$180.00
+17%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Revenue growth
0.80%
Profit margin
22.50%
Debt to equity
116.85
Analyst consensus
Hold · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 31.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 10.3% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 1.2% of assets, under the 49% limit.Pass
Revenue purityOnly 1.7% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Swiss pharma name below calculated fair value
Patients take heart failure medicines like Entresto every day and Novartis collects the revenue. The shares sit at 153.76 dollars against our 180 fair value, a 17 percent margin of safety. Forward earnings are 15.8 times while profit margins reach 24 percent and return on equity hits 35 percent even as revenue edges down one percent.
The business clears the ethical screen and shows consistent cash generation in a defensive sector. That gap to fair value drives the opportunity rating despite ten analysts holding a 152 dollar median target.
Revenue contraction and an unknown moat are real concerns that could point to future patent pressure or pricing power loss. Currency swings from its Swiss base add further volatility for investors.
Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Switzerland and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
NVS trades on NYSE (ADR) (the company is based in Switzerland). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis. Entered 2026-07-21 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-21Markup$153.76+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markup$153.76+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Markup$153.76+0.5%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$153.07+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Markup$153.07+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Markup$153.07+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it hold, with a mean price target of $154. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Markup$153.07+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$153.07Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$145.23
+2.1%
·
$1,021
+2.1%
2 months
$154.05
-3.8%
·
$962
-3.8%
3 months
$154.25
-3.9%
·
$961
-3.9%
6 months
$128.45
+15.4%
$4.77
$1,191
+19.1%
1 year
$115.08
+28.8%
$4.77
$1,330
+33.0%
2 years
$98.62
+50.3%
$8.77
$1,592
+59.2%
3 years
$90.99
+62.9%
$12.51
$1,766
+76.6%
5 years
$76.87
+92.8%
$19.33
$2,180
+118.0%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever NVS does next, these words stay.
Novartis AG · NVS · Markup · $154.44
Recorded 2026-08-05 · before the outcome · scored mechanically
